News articles about Codexis (NASDAQ:CDXS) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2389476269391 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Codexis (CDXS) opened at $8.35 on Tuesday. Codexis has a twelve month low of $3.60 and a twelve month high of $9.45. The company has a market capitalization of $414.19, a P/E ratio of -12.85 and a beta of -1.59.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). Codexis had a negative net margin of 76.37% and a negative return on equity of 140.02%. The company had revenue of $9.98 million for the quarter, compared to analyst estimates of $10.00 million. equities research analysts expect that Codexis will post -0.46 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Codexis (CDXS) Stock Price” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2018/01/23/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-codexis-cdxs-stock-price.html.
Codexis Company Profile
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.